Browsing by Author "Ubanako, Philemon"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Efficacy of co‑loading Ag nanoparticles and metronidazole in PEG–gelatin‑based sponges for the treatment of chronic wounds
    (Springer, 2023-08-07) Alven, Sibusiso; Adeyemi, S.A.; Ubanako, Philemon; Nditheh, D.T.; Choonara, Yahya Essop; Aderibigbe, Blessing A.
    Polymer-based sponges loaded with antibacterial agents are potential wound dressings ideal for treating bacteria-infected wounds. Gelatin/poly (ethylene glycol) (PEG) sponge-based wound dressings loaded with metronidazole and Ag nanoparticles with different degrees of cross-linking were prepared, and their capability to treat infected wounds in vitro was evaluated. The degree of cross-linking of the sponges varied, and the porosity of the sponges was in the range of 15.64–91.10%. The amount of gelatin used to prepare the sponges influenced the porosity of the sponges. The sponges displayed an initial burst drug release of metronidazole followed by a sustained release profile. The sponges exhibited considerable antibacterial activity against Gram-positive and Gram-negative bacteria. The % cell viability of the sponges was in the range of 71.17–86.10%, indicating distinguished biocompatibility. The in-vitro experiment showed that the sponge loaded with metronidazole, SAM2%, displayed a significant reduction of 66.68% in the scratch area compared to the sponge loaded with a combination of silver nanoparticles and metronidazole with a closure rate of 46.61% at 96 h. The promising features of the sponges indicate that they are potential wound dressings for treating infected wounds.
  • Thumbnail Image
    Item
    Novel ferrocenylbisphosphonate hybrid compounds: Synthesis, characterization and potent activity against cancer cell lines
    (2022-02-02) Anusionwu, Chioma G.; Aderibigbe, Blessing A. ; Adeyemi, Samson A.; Ubanako, Philemon; Oselusi, Samson O.; Choonara, Yahya E.; Mbianda, Xavier Yangkou
    The toxicity of existing anticancer agents on healthy cells and the emergence of multidrug-resistance cancer cells have led to the search for less toxic anticancer agents with different mechanisms of action. In this study, a novel class of ferrocenylbisphosphonate hybrid compounds (H1-H8) were designed and characterized using NMR, IR and HRMS. The in vitro anticancer activity of the hybrid compounds on HeLa (cervix adenocarcinoma) and A549 (non-small cell lung cancer cell lines) was evaluated. The structure–activity relationship of the hybrid molecules was also studied. The lead compound, tetraethyl (3-(4-oxo-4-ferrocenylbutanamido) propane-1-1-diylbis (phosphonate) (H6) exhibited higher cytotoxicity on A549 (IC50 = 28.15 µM) than cisplatin (IC50 = 58.28 µM), while its activity on HeLa cells (IC50 = 14.69 µM) was equivalent to that of cisplatin 15.10 µM (HeLa cells). H6 (IC50 = 95.58 µM) was also five times less toxic than cisplatin (IC50 = 20.86 µM) on fibroblast NIH3T3 suggesting that H6 can be a future replacement for cisplatin due to its non-toxicity to healthy cells. Interestingly, some ferrocene and bisphosphonate parent compounds exhibited promising anticancer activity with 4-ferrocenyl-4-oxobutanoic acid (FI) exhibiting higher cytotoxic activity (IC50 = 1.73 µM) than paclitaxel (IC50 = 3.5 µM) on A549 cell lines. F1 also exhibited lower cytotoxicity than paclitaxel and cisplatin on the normal murine fibroblast cell line (NIH3T3). The molecular docking studies showed H6 strong binding affinity for the STAT3 signaling pathway in A549 cell line, and the MAdCAM-1 and cellular tumor antigen p53 proteins in HeLa cell lines.